Fluoroquinolone-based versus β-lactam-based regimens for complicated intra-abdominal infections: a meta-analysis of randomised controlled trials

Outcomes of Beta-Lactam Allergic and Non-Beta-Lactam Allergic Patients with Intra-Abdominal Infection: A Case–Control Study

“…Our results are in agreement with those presented in a recent meta-analysis [ 15 ] pooling seven RCTs that reported the non-inferiority of fluoroquinolone-based regimens compared to BL-based regimens for complicated IAI [ 16 , 17 , 18 , 19 , 20 , 21 , 22 ]. Importantly, our study provides some recent data on the efficacy and safety of aztreonam-based regimens in IAI, which are otherwise lacking.…”

“…Second, the retrospective and monocentric design of the study could have introduced bias in data collection and limit result generalization. Nonetheless, the rates of therapeutic success in our cohort were consistent with those previously reported [ 15 ] as was the rate of healthcare-associated infections [ 51 , 52 ]. Third, we used the Apache II score to evaluate the severity of illness in patients who were not all hospitalized in ICU, which is the setting for which it was validated [ 53 ].…”

“…Due to its good to excellent antimicrobial activity against Enterobacterales and most anaerobic microorganisms, moxifloxacin monotherapy has been proposed for patients with IAI [ 31 ]. However, a recent meta-analysis [ 15 ] suggested moxifloxacin was slightly inferior to BL, reigniting the debate on the use of fluoroquinolones in IAI. In our work, as in most clinical trials evaluating fluoroquinolones versus cephalosporins for IAI management [ 15 ], the anaerobes coverage is provided by the use of metronidazole, although its use is not mandatory in patients treated with piperacillin–tazobactam or imipenem [ 29 ].…”

Carbapenems vs tigecycline for the treatment of complicated intra-abdominal infections

“…[12] The choice of therapy is physician oriented and is based on the local bacterial epidemiology, the infection site, acquisition (community acquired, health care associated or hospital acquired) and risk for treatment failure and death. [45]…”

Systematic Literature Review of Real-world Evidence of Ceftolozane/Tazobactam for the Treatment of Respiratory Infections

“…These included, but were not limited to, the different components of effect modification observed within antibacterial evidence, the variability in pathogen susceptibility, infection types, causative pathogens, and changes of definitions over time. These challenges and limitations of quantitative analyses due to the heterogeneity of results have also been highlighted in the literature [48][49][50][51].…”